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Abstract
At present only few biological data are available to indicate
whether psoriatic arthritis (PsA) is part of the
spondyloarthropathy (SpA) concept, whether it is a separate
disease entity or a heterogeneous disease group with
oligoarticular/axial forms belonging to SpA and polyarticular
forms resembling rheumatoid arthritis (RA). To address this
issue with regard to peripheral synovitis, we compared the
synovial characteristics of PsA with those of ankylosing
spondylitis (AS)/undifferentiated SpA (USpA) and RA, and
compared the synovium of oligoarticular versus polyarticular
PsA. Synovial biopsies were obtained from patients with RA,
nonpsoriatic SpA (AS + USpA), and oligoarticular and
polyarticular PsA. The histological analysis included
examination(s) of the lining layer thickness, vascularity, cellular
infiltration, lymphoid aggregates, plasma cells and neutrophils.
Also, we performed immunohistochemical assessments of CD3,
CD4, CD8, CD20, CD38, CD138, CD68, CD163, CD83,
CD1a, CD146, αVβ3, E-selectin, intercellular adhesion
molecule-1, vascular cell adhesion molecule-1, S100A12,
intracellular citrullinated proteins and major histocompatibility
complex (MHC)–human cartilage (HC) gp39 peptide
complexes. Comparing SpA (PsA + AS + USpA) with RA,
vascularity, and neutrophil and CD163+ macrophage counts
were greater in SpA (P < 0.05), whereas lining layer thickness
and the number of CD83+ dendritic cells were greater in RA (P
< 0.05). In RA, 44% of samples exhibited positive staining for
intracellular citrullinated proteins and 46% for MHC–HC gp39
peptide complexes, whereas no staining for these markers was
observed in SpA samples. We excluded influences of disease-
modifying antirheumatic drug and/or corticosteroid treatment by
conducting systematic analyses of treated and untreated
subgroups. Focusing on PsA, no significant differences were
observed between PsA and nonpsoriatic SpA. In contrast,
vascularity (P < 0.001) and neutrophils were increased in PsA
as compared with RA (P  = 0.010), whereas staining for
intracellular citrullinated proteins and MHC–HC gp39 peptide
complexes was exclusively observed in RA (both P = 0.001),
indicating that the same discriminating features are found in PsA
and other SpA subtypes compared with RA. Exploring synovial
histopathology between oligoarticular and polyarticular PsA, no
significant differences were noted. Moreover, intracellular
citrullinated proteins and MHC–HC gp39 peptide complexes,
which are specific markers for RA, were observed in neither
oligoarticular nor polyarticular PsA. Taken together, these data
indicate that the synovial histopathology of PsA, either
oligoarticular or polyarticular, resembles that of other SpA
subtypes, whereas both groups can be differentiated from RA
on the basis of these same synovial features, suggesting that
peripheral synovitis in PsA belongs to the SpA concept.
ACR = American College of Rheumatology; AS = ankylosing spondylitis; DMARD = disease-modifying antirheumatic drug; ESSG = European 
Spondyloarthropathy Study Group; HC = human cartilage; ICAM = intercellular adhesion molecule; MHC = major histocompatibility complex; MMP 
= matrix metalloproteinase; MRP = myeloid-related protein; PMC = polymorphonuclear cell; PsA = psoriatic arthritis; RA = rheumatoid arthritis; RANK 
= receptor activator of nuclear factor-κB; SpA = spondyloarthropathy; USpA = undifferentiated spondyloarthropathy; VCAM = vascular cell adhesion 
molecule.Arthritis Research & Therapy    Vol 7 No 3    Kruithof et al.
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Introduction
Psoriatic arthritis (PsA) is a chronic inflammatory autoimmune
disease that is characterized by inflammatory arthritis and skin
psoriasis. It is commonly classified as a subtype of the spond-
yloarthropathy (SpA) concept, together with ankylosing
spondylitis (AS), reactive arthritis, arthritis associated with
inflammatory bowel disease, and undifferentiated spondyloar-
thropathy (USpA) [1]. Indeed, PsA shares a number of pheno-
typic characteristics with the other SpA subtypes, such as
asymmetrical synovitis, enthesitis and familial aggregation.
Typical SpA features such as sacroiliitis, presence of HLA-
B27, uveitis and chronic inflammatory gut lesions are also
found in PsA, albeit at a lower frequency than in other SpA
subtypes [2-4]. Interestingly, the peripheral joint involvement is
mostly asymmetrical and oligoarticular, as in SpA, but can also
mimic rheumatoid arthritis (RA) with eventually destructive
involvement of multiple small hand and feet joints [5]. Finally,
skin and nail involvement, total ankylosis of destructed periph-
eral joints, predominant distal interphalyngeal joint involvement
and arthritis mutilans sets PsA apart from both SpA and RA.
Therefore, there is at present no clear consensus regarding
whether PsA belongs to the SpA concept, whether it is a sep-
arate disease entity, or whether it is a heterogeneous disease
group with oligoarticular and axial forms belonging to the SpA
concept on the one hand and destructive, polyarticular forms
resembling RA on the other [6,7]. This question will probably
only be answered once the pathogenesis of the disease is fully
elucidated, leading to an aetiological rather than phenotypical
disease classification.
In previous histopathological synovial studies we considered
PsA as part of the SpA concept and compared it as such with
other inflammatory joint diseases. Although some early data
are available on PsA synovial histology based on small studies
of surgical or blind needle specimens, only few studies sys-
tematically evaluated PsA synovium obtained from actively
inflamed joints [8,9]. Moreover, most of those studies used RA
as a control and did not compare PsA and nonpsoriatic SpA,
or oligoarticular and polyarticular PsA. In this context it must be
highlighted that the few reports dealing with PsA synovium did
not specify whether these patients had oligoarticular or polyar-
ticular disease. The present study is the first to address these
issues systematically and quantitatively in a large set of
actively inflamed synovium samples by (1) conducting a
detailed analysis of PsA synovitis in comparison with AS–
USpA on the one hand and RA on the other, using a large
panel of histopathological features; (2) comparing oligoarticu-
lar versus polyarticular PsA with respect to synovial features
that discriminate between RA and SpA; and (3) analyzing the
expression of S100A12, which was reported to be an interest-
ing marker in PsA [10].
Materials and methods
Patients
In accordance with the aims of the study, three different
patient cohorts were included. Cohort 1 was considered in the
comparison of synovial histopathology between PsA, AS–
USpA and RA. It included 22 patients with PsA having asym-
metrical peripheral synovitis and skin psoriasis, and moreover
fulfilling the European Spondyloarthropathy Study Group
(ESSG) criteria [11], 28 nonpsoriatic SpA patients fulfilling
the ESSG criteria (including 13 AS patients diagnosed
according to the modified New York criteria [12] and 15 USpA
patients), and 52 RA patients fulfilling the American College of
Rheumatology (ACR) criteria [13]. Of the 22 PsA patients, six
had a swollen joint count of more than 5 but with predominant
involvement of the lower limbs and presence of other charac-
teristics of SpA (i.e. enthesitis, sacroiliitis, familial history, etc.).
None of them fulfilled the ACR criteria for RA [13]. Demo-
graphic and clinical features are summarized in Table 1.
Cohort 2 included a large number of PsA patients (n = 45),
permitting us to compare synovial histopathology between oli-
goarticular and polyarticular disease. Of these patients 28 had
oligoarticular disease with involvement of fewer than 5 periph-
eral joints, and the remaining 17 patients had polyarticular dis-
ease (≥ 5 joints). Demographic and clinical features are
summarized in Table 2.
Cohort 3 was considered in the analysis of S100A12 by
immunohistochemistry of synovial tissue. It included eight PsA
patients (fulfilling the ESSG criteria [11]), 12 nonpsoriatic
SpA patients (according to the ESSG criteria) and 20 RA
patients fulfilling the ACR criteria [13]. The demographic and
clinical features of these patients are summarized in Table 3.
Since we demonstrated previously that synovial histopathol-
ogy is influenced by local disease activity in SpA and RA, all
included patients were required to have a clinical effusion of at
least one knee joint to perform needle arthroscopy with syno-
vial biopsy sampling [14]. Written informed consent was
obtained from all patients before their inclusion in the study,
which was approved by the Ethics Committee of the Ghent
University Hospital.
Synovial histopathology
Synovial biopsies (16 per patient) were obtained by needle
arthroscopy of the knee as described previously [15]. Eight
biopsies were stored in formaldehyde and embedded in paraf-
fin, and eight biopsies were snap frozen and mounted in Jung
tissue freezing medium (Leica Instruments, Nussloch, Ger-
many) and utilized for immunohistochemistry. The procedure
for histological and immunohistochemical analysis of the differ-
ent markers was extensively described and validated previ-
ously [14,16-20]. Briefly, paraffin-embedded biopsies were
stained with haematoxylin and eosin for histological analysis,
including mean synovial lining layer thickness (score: 1 =Available online http://arthritis-research.com/content/7/3/R569
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Table 1
Demographic and clinical features of patients with PsA, nonpsoriatic SpA (AS + USpA) and RA.
Parameter PsA Nonpsoriatic SpA RA
Number of patient 22 28 52
Sex (male/female) 14/8 22/6 25/27
Age (years) 45.6 ± 11.0 43.3 ± 13.7 54.0 ± 14.9
Disease duration (years) 10.1 ± 11.5 8.4 ± 9.8 4.9 ± 6.2
Number of swollen joints 4.1 ± 4.0 3.7 ± 4.0 10.5 ± 6.8
Serum CRP (mg/dl) 2.1 ± 1.9 4.0 ± 5.8 6.0 ± 7.4
ESR (mm/hour) 23.6 ± 22.2 30.1 ± 30.5 35.7 ± 27.1
Rheumatoid factor (+/-) 0/21 1/26 36/13
NSAID (+/-) 15/7 25/3 38/14
DMARD (+/-) 6/16 7/21 21/31
Corticosteroids (+/-) 1/21 2/26 12/40
The nonpsoriatic SpA subgroup includes 13 patients with AS and 15 with USpA. Values are expressed as mean ± standard deviation or as 
numbers. AS, ankylosing spondylitis; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation 
rate; NSAID, nonsteroidal anti-inflammatory drug; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SpA, spondyloarthropathy; USpA, 
undifferentiated spondyloarthropathy.
Table 2
Demographic and clinical features of patients with oligoarticular and polyarticular PsA.
Parameter Oligoarticular PsA Polyarticular PsA
Number of patients 28 17
Sex (male/female) 20/8 9/8
Age (years) 42.6 ± 10.9 43.7 ± 10.7
Disease duration (years) 7.4 ± 8.4 11.9 ± 11.1
Number of swollen joints 1.7 ± 1.0 9.2 ± 4.2
Serum CRP (mg/dl) 2.3 ± 3.6 3.4 ± 2.2
ESR (mm/hour) 19.2 ± 18.2 40.8 ± 21.1
Rheumatoid factor (positive/negative) 0/28 0/17
Sacroiliitis (≥grade II; +/-) 2/15 4/12
Enthesitis (+/-) 6/14 10/6
Hand joint involvement (+/-) 9/12 14/3
Symmetrical joint involvement (+/-) 4/19 10/7
DIP joint involvement (+/-) 8/11 10/7
NSAID (+/-) 21/6 15/1
DMARD (+/-) 8/19 10/6
Corticosteroids (treated/untreated) 2/25 3/13
Demographic and clinical features of patients with oligoarticular and polyarticular PsA. Values are expressed as mean ± standard deviation or as 
numbers. CRP, C-reactive protein; DIP, distal interphalangeal joint; DMARD, disease-modifying antirheumatic drugs; ESR, erythrocyte 
sedimentation rate; NSAID, nonsteroidal anti-inflammatory drug.Arthritis Research & Therapy    Vol 7 No 3    Kruithof et al.
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mean of 1–2 cell layers, 2 = mean of 3–5 cell layers, 3 = mean
of >5 cell layers), vascularity of the sublining layer, global cel-
lular infiltration of the sublining layer, and presence of lymphoid
aggregates, plasma cells and polymorphonuclear cells
(PMCs). Frozen sections of the synovial biopsies were stained
with the following antibodies (from Dako [Glostrup, Denmark],
unless otherwise stated): anti-CD3 (T cells, clone UCHT1),
anti-CD4 (T-helper cells, clone MT310), anti-CD8 (cytotoxic T
cells, clone DK25), anti-CD20 (B cells, clone L26), anti-CD38
(plasma cells, clone AT13/5), anti-CD138 (plasma cells, clone
CBL455; Chemicon, Temecula, CA, USA), anti-CD68 (pan-
macrophage marker expressed on monocytes and macro-
phages, clone EBM11), anti-CD163 (scavenger receptor
expressed on resident tissue macrophages, clone Ber-
MAC3), anti-CD83 (dendritic cells, clone HB15A; Immu-
notech SA, Marseille, France), anti-CD1a (interdigitating den-
dritic cells, clone NA1/34), anti-CD146 (endothelial cells,
clone P1H12; Chemicon), anti-αVβ3 (CD51/CD61, integrin
expressed on endothelial cells, fibroblasts, osteoclasts, etc.,
clone LM609; Chemicon), anti-E-selectin (CD62E, endothelial
leucocyte adhesion molecule 1, clone 1.2B6), anti-ICAM-1
(CD54, intercellular adhesion molecule [ICAM]-1, clone
6.5B5), anti-VCAM-1 (CD106, vascular cell adhesion mole-
cule [VCAM]-1, clone 1.4C3), the rabbit polyclonal anti-L-cit-
rulline antibody (citrullinated peptides; Biogenesis, Poole, UK),
and Mab-12A (detecting major histocompatibility complex
[MHC] class II–human cartilage [HC] gp39 peptide com-
plexes; NV Organon, Oss, The Netherlands) [18,21]. Immu-
nostaining for S100A12 (calgranulin C) was performed with
polyclonal affinity-purified rabbit antisera against human
S100A12 (a S100A12) [22].
It should be noted that the scavenger receptor CD163 identi-
fies a subset of CD68+ macrophages that is specifically
increased in SpA synovium and gut, and which could play an
important role in innate immune inflammation of these tissues
[16,19].
After incubation with the primary antibody, sections were
sequentially incubated with a biotinylated second antibody, a
streptavidine–horseradish peroxidase link, and finally with
amino-ethyl-carbazole substrate as chromogen. Parallel sec-
tions were incubated with irrelevant isotype and concentration
matched monoclonal antibody as negative control. Sections
were coded and analyzed semiquantitatively on a 4-point scale
(0–3) by two independent observers who were blinded to
diagnosis and clinical data. Because the numbers of positive
cells per synovial section for citrullinated peptides and Mab-
12A were too small to be scored semiquantitatively, these
parameters were scored as present or absent. The analysis
included all areas of the eight biopsies and a global score was
given for each parameter, using a semiquantitative 4-point
scale (0 = lowest level of expression, 3 = highest level of
expression) [14,16-21]. Because some histological markers
are more abundant than others, the scoring system was cali-
brated for each marker separately by examining a representa-
tive number of samples. The scores obtained by the two
observers were concordant in more than 95% of cases. In the
event of discordant scores, which differed by a maximum of 1
point, the mean of the two scores was used.
Statistics
Because the semiquantitative data are nonparametric, these
data are presented as median (range). Differences between
groups were analyzed using the nonparametric Mann–Whit-
ney U-test. For markers scored as present or absent, the χ2
test was used. Bonferroni adjustment of alpha was performed
where indicated. P < 0.05, after Bonferroni correction, was
considered statistically significant.
Results
Synovial histopathology of spondyloarthropathy versus 
rheumatoid arthritis
We previously established the differences between SpA
(including PsA fulfilling ESSG criteria) and RA in terms of glo-
bal synovial histology and infiltrating cell populations [14,16].
Therefore, in patient cohort 1 we compared the following syn-
ovial features between the pooled SpA group (50 samples)
and the RA group (52 patients): lining layer thickness, vascu-
larity, global cellular infiltration, lymphoid follicles, plasma cells,
PMCs, CD3, CD4, CD8, CD20, CD38, CD138, CD68,
CD163, CD1a, CD83, CD146, αVβ3, E-selectin, ICAM-1,
VCAM-1, intracellular citrullinated proteins and MHC–HC
gp39 peptide complexes.
As shown in Table 4, the lining layer thickness (P = 0.006) and
number of CD83+ dendritic cells (P = 0.006) were signifi-
cantly greater in RA than in SpA. There was also a trend
toward greater CD38+ plasma cell infiltration in RA than in
SpA (P = 0.060). On the contrary, vascularity (P < 0.001),
infiltration with PMCs (P  = 0.008), and the presence of
CD163+ macrophages in the lining layer (P = 0.033) and sub-
lining layer (P = 0.031) were higher in SpA (although the medi-
ans for PMC infiltration did not differ, reflecting that only a
subset of SpA samples was characterized by high degree of
PMC infiltration). In agreement with previous studies [16,19],
the increase in the CD163+ macrophage subset in SpA was
not parallalled by changes in the global number of macro-
phages, as detected by the panmacrophage marker CD68.
ICAM-1 staining in the synovial lining layer (P = 0.025), but not
in the sublining or on the vascular endothelium, was also
higher in SpA than in RA. Intracellular citrullinated proteins and
MHC–HC gp39 peptide complexes were observed only in RA
patients (44% positive for citrullinated proteins and 46% pos-
itive for MHC–HC gp39 peptide complexes), with absence of
staining for these markers in the SpA samples (for both: P <
0.001).
There were no other significant differences between both
groups. Taken together these data confirm our previous obser-Available online http://arthritis-research.com/content/7/3/R569
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vations and indicate that the samples selected for the study
are representative of the global histopathological picture of
SpA and RA. The differences are illustrated in Fig. 1.
Influence of disease-modifying antirheumatic drug and 
steroid treatment on synovial histopathology
Because the studied disease groups in cohort 1 received dif-
ferent therapies (Table 1) and because previous longitudinal
studies with paired biopsy sampling have demonstrated the
effect of disease-modifying antirheumatic drugs (DMARDs)
and systemic corticosteroids on synovial histopathology [23-
27], we assessed whether DMARD and/or systemic corticos-
teroid therapy could bias a cross-sectional histopathological
evaluation of clinically involved joints.
As shown in more detail in Table 1, six out of 22 PsA patients,
eight out of 28 AS–USpA patients, and 25 out of 52 RA
patients were treated with DMARDs and/or systemic corticos-
teroids. For the RA group, we compared patients with versus
those without DMARD treatment, as well as patients with ver-
sus those without corticosteroid treatment with respect to the
synovial features mentioned above. Only endothelial VCAM-1
(higher in RA with than in RA without DMARD treatment: 2.0
[0–3.0] versus 0 [0–3.0]; P = 0.035) and endothelial E-selec-
tin (lower in RA with than in RA without corticosteroid treat-
ment: 0.5 [0–1.5] versus 1.5 [0–3.0]; P  = 0.017) were
significantly different as a function of treatment.
For the SpA group (PsA + AS + USpA), we compared 13
DMARD-treated patients with 37 patients who received no
DMARD treatment. Only ICAM-1 expression was significantly
different as a function of DMARD treatment (lower in SpA with
than in SpA without DMARD treatment: 2.5 [1.0–3.0] versus
3.0 [1.5–3.0] for the lining layer [P = 0.033], and 1.0 [0–2.5]
versus 2.5 [0–3.0] for the sublining layer [P = 0.003]).
Focusing on the PsA group, a comparison of patients with ver-
sus those without DMARD treatment for the same parameters
revealed no significant differences.
Synovial histopathology of psoriatic arthritis versus 
rheumatoiad asthritis and versus ankylosing 
spondylitis–undifferentiated spondyloarthropathy
Having confirmed histopathological differences between RA
and SpA synovitis and having excluded a systemic bias intro-
duced by therapy, we then focused more specifically on PsA.
Using the same histological markers, in patient cohort 1 we
compared 22 PsA with 52 RA synovia samples. The degree of
synovial vascularity was higher in PsA (median 2.5 [range 1.0–
3.0]) than in RA (1.5 [1.0–3.0]; P < 0.001). Similarly, the pres-
ence of PMCs was more pronounced in PsA (0.5 [0–3.0])
than in RA (0 [0–2.5]; P = 0.010). Intracellular citrullinated
proteins and MHC–HC gp39 peptide complexes were not
observed in PsA, whereas 44% of RA samples were positive
for citrullinated proteins and 46% were positive for MHC–HC
gp39 peptide complexes (for both: P = 0.001). There was no
significant difference for the other investigated markers,
including E-selectin and CD68, which were previously
reported to be different between both diseases [8]. Perform-
ing a similar analysis in function of AS–USpA, we compared
the 22 PsA samples with 28 nonpsoriatic SpA samples (13
AS and 15 USpA); none of the investigated markers was sig-
nificantly different between both groups.
Oligoarticular versus polyarticular psoriatic arthritis
It was previously suggested that PsA could comprise different
subsets, including an oligoarticular subtype that resembles
Table 3
Demographic and clinical features of patients with PsA, nonpsoriatic SpA and RA
Parameter PsA Nonpsoriatic SpA RA
Number of patients 8 12 20
Sex (male/female) 4/4 9/3 8/12
Age (years) 45.1 ± 7.1 39.7 ± 8.9 58.9 ± 17.2
Disease duration (years) 6.0 ± 9.7 6.6 ± 6.0 4.5 ± 7.9
Number of swollen joints 3.0 ± 1.9 2.6 ± 3.1 11.7 ± 8.3
Serum CRP (mg/dl) 6.2 ± 6.5 4.3 ± 5.1 7.3 ± 7.4
ESR (mm/hour) 36.4 ± 34.7 23.8 ± 25.2 44.2 ± 28.9
Rheumatoid factor (+/-) 0/8 0/11 14/6
DMARD (+/-) 3/3 8/4 8/12
Corticosteroids (+/-) 1/5 0/12 9/11
The nonpsoriatic SpA subgroup includes six AS and six USpA patients. Values are expressed as mean ± standard deviation. AS, ankylosing 
spondylitis; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; NSAID, nonsteroidal 
anti-inflammatory drug; PsA, psoriatic arthritis; RA, rheumatoid arthritis; USpA, undifferentiated spondyloarthropathy.Arthritis Research & Therapy    Vol 7 No 3    Kruithof et al.
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SpA and a polyarticular form mimicking RA. To address this
issue, we constituted a new PsA cohort (patient cohort 2)
including 28 patients with oligoarticular disease (<5 swollen
joints) and 17 patients with polyarticular PsA (≥ 5 swollen
joints). We compared the PsA subgroups with respect to
those synovial features that appeared to discriminate best
between SpA and RA in the previous experiments or that have
been reported in the literature [8]: lining layer hyperplasia, vas-
cularity, PMCs, CD163+ and CD68+ macrophages, and
expression of E-selectin. As shown in Table 5, no significant
differences in these parameters were observed between oli-
goarticular and polyarticular PsA. Again, intracellular citrulli-
nated proteins and MHC–HC gp39 peptide complexes – two
Table 4
Comparison of histological markers between SpA (PsA + AS + USpA) synovium and RA synovium
Marker SpA (n = 50) RA (n = 52) P
Lining layer thickness 1.0 (1.0–2.5) 2.0 (0–3.0) 0.006
Vascularity 2.0 (1.0–3.0) 1.5 (1.0–3.0) <0.001
Cellular infiltration 1.5 (0–3.0) 2.0 (0–3.0) 0.120
Lymphoid follicles 0 (0–3.0) 0 (0–3.0) 0.232
Plasma cells 0.5 (0–3.0) 0.5 (0–3.0) 0.497
Polymorphonuclear cells 0 (0–3.0) 0 (0–2.5) 0.008
CD3 1.5 (0–3.0) 2.0 (0–3.0) 0.152
CD4 1.0 (0–3.0) 1.0 (0–3.0) 0.192
CD8 1.0 (0–3.0) 1.5 (0–3.0) 0.737
CD20 1.0 (0–3.0) 2.0 (0–3.0) 0.231
CD38 1.5 (0–3.0) 2.0 (0–3.0) 0.060
CD138 1.0 (0–3.0) 2.0 (0–3.0) 0.447
CD68 lining 1.0 (0–3.0) 1.0 (0–3.0) 0.631
CD68 sublining 1.5 (0–3.0) 1.5 (0.5–3.0) 0.957
CD163 lining 2.0 (0–3.0) 1.5 (0–3.0) 0.033
CD163 sublining 1.5 (0–3.0) 1.0 (0–2.5) 0.031
CD1a 0 (0–3.0) 1.0 (0–3.0) 0.121
CD83 0 (0–1.0) 0 (0–3.0) 0.006
CD146 2.0 (0–3.0) 0 (0–3.0) 0.075
αVβ3 lining 1.0 (0–3.0) 1.0 (0–3.0) 0.397
αVβ3 sublining 1.0 (0–3.0) 1.0 (0–3.0) 0.306
E-selectin blood vessels 1.0 (0–3.0) 1.5 (0–3.0) 0.760
ICAM-1 lining 3.0 (1.0–3.0) 2.5 (0–3.0) 0.025
ICAM-1 sublining 2.0 (0–3.0) 2.0 (0–3.0) 0.654
ICAM-1 blood vessels 2.5 (0.5–3.0) 2.5 (0–3.0) 0.652
VCAM-1 lining 3.0 (0–3.0) 3.0 (0–3.0) 0.077
VCAM-1 sublining 1.5 (0–3.0) 1.5 (0–3.0) 0.473
VCAM-1 blood vessels 1.0 (0–3.0) 1.5 (0–3.0) 0.997
Intracellular citrullinated proteins 0% 44% <0.001
Mab-12A 0% 46% <0.001
The Mann–Whitney U-test was used to evaluate markers scored semiquantitatively, and the χ2 test was used to evaluate markers scored as 
present or absent. Results are expressed as median (range), and markers evaluated as present or absent are expressed as percentage of positive 
results. P < 0.05 was considered statistically significant. AS, ankylosing spondylitis; ICAM, intercellular adhesion molecule; PsA, psoriatic arthritis; 
RA, rheumatoid arthritis; USpA, undifferentiated spondyloarthropathy; VCAM, vascular cell adhesion molecule.Available online http://arthritis-research.com/content/7/3/R569
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Figure 1
Synovial histology in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and nonpsoriatic spondyloarthropathy (ankylosing spondylitis  [AS] + undifferentiated spondyloarthropathy [USpA]) Synovial histology in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and nonpsoriatic spondyloarthropathy (ankylosing spondylitis 
[AS] + undifferentiated spondyloarthropathy [USpA]). Synovial biopsies from RA, PsA and spondyloarthropathy (SpA; AS/USpA) patients were 
scored on a semiquantitative scale (0–3) by two independent observers. Representative sections of RA and PsA and nonpsoriatic SpA synovium are 
shown, and the corresponding semiquantitative score for each picture is indicated. The evaluated parameters included synovial lining layer thick-
ness, CD83+ dendritic cells, CD38+ plasma cells, degree of vascularity, number of neutrophils (polymorphnuclear neutrophils [pmn]) and CD163+ 
macrophages.Arthritis Research & Therapy    Vol 7 No 3    Kruithof et al.
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markers specific for RA – were not observed in either the oli-
goarticular or polyarticular PsA samples.
S100A12
Finally, we investigated whether, apart from the well known
histopathological markers evaluated in the previous experi-
ments, additional specific immunohistochemical stainings
were helpful in the evaluation of PsA synovitis compared with
nonpsoriatic SpA and RA. Based on the greater infiltration
with PMCs in SpA than in RA, and a recent report on the gran-
ulocyte calcium-binding protein S100A12 in PsA [10], we
assessed the expression of S100A12 in synovium of patients
with PsA (n = 8), nonpsoriatic SpA (n = 12) and RA (n = 20;
patient cohort 3; Table 3). Cellular staining for S100A12 was
observed in the sublining layer in all three patient subgroups,
whereas staining in the lining layer was only occasionally
observed (Fig. 2). Confirming the findings of the previous
study [10], S100A12 expressing cells were found essentially
in perivascular infiltrates, either adjacent to small blood ves-
sels or adhering to endothelial cells. However, this staining
pattern was observed in all groups without clear distinction
between PsA, nonpsoriatic SpA and RA. This difference may
be accounted for by the fact that, in the study conducted by
Foell and coworkers [10], the disease duration of the patients
at study entry was shorter, and none of the PsA-patients
received any DMARDs or steroids. Moreover, there was no
significant difference in the degree of staining between PsA
(median 1 [range 0–3]) and nonpsoriatic SpA (1, [0–2]; P =
1.000) or RA (median 0 [0–3]; P = 0.430). Pooling of the PsA
and nonpsoriatic SpA samples in one SpA group did not result
a difference between SpA and RA either (P = 0.096).
Discussion
Because the synovial membrane is one of the primary tissue
targets in PsA, detailed histopathological analysis of PsA syn-
ovitis might be a useful approach to gain new insights into this
disease and to analyze biological similarities with or differ-
ences from other chronic inflammatory joint disorders such as
RA and SpA. This is of particular importance because PsA is
thought to resemble either RA or SpA, depending on the clin-
ical pattern of peripheral joint involvement, with respectively
polyarticular symmetrical disease and oligoarticular asymmet-
rical involvement. In this context, a detailed analysis of the syn-
ovial histopathology in PsA not only may provide new insights
in the disease process but also may help to provide a biologi-
cal rationale for the classification of PsA. However, until now
such analyses are lacking.
Synovial histopathology in PsA is generally characterized by
neovascularization, and inflammatory infiltration with predomi-
nantly mononuclear cells (T lymphocytes, B lymphocytes and
plasma cells, and macrophages), although PMCs can also be
detected [28]. Mild to moderate synovial lining hyperplasia is
observed in a considerable percentage of cases. Whereas
these characteristics are found as well in other types of
inflammatory arthritis, the availability of synovial biopsies from
needle arthroscopy and new histopathological tools (mono-
clonal antibodies, RNA probes) have permitted a more
detailed comparison of PsA and RA synovitis. One of the most
prominent differences was the higher degree and typical mor-
phology of synovial vascularity, which appeared to be related
to angiogenic factors such as vascular endothelial growth fac-
tor, matrix metalloproteinase (MMP)-9 and angiopoietins, and
was accompanied by a higher expression of E-selectin
[8,29,30]. Lining layer hyperplasia appeared to be more pro-
nounced in RA, both by altered apoptosis of lining cells as by
Table 5
Comparison of histological markers between oligoarticular and polyarticular PsA
Marker Oligoarticular PsA (n = 28) Polyarticular PsA (n = 17) P
Lining layer thickness 1.0 (1.0–3.0) 1.0 (1.0–2.0) 0.492
Vascularity 1.5 (0–3.0) 2.0 (0–3.0) 0.661
Polymorphonuclear cells 0 (0–3.0) 0 (0–2.5) 0.126
CD68 lining 2.0 (0–3.0) 2.0 (0–2.0) 0.478
CD68 sublining 1.5 (0–3.0) 1.0 (0–3.0) 0.845
CD163 lining 2.0 (0–3.0) 2.0 (0.5–3.0) 0.768
CD163 sublining 1.5 (0–2.5) 1 (0–2.5) 0.935
E-selectin blood vessels 0 (0–3.0) 0.25 (0–2.5) 0.594
Intracellular citrullinated proteins 0% 0% 1.000
Mab-12A 0% 0% 1.000
The Mann–Whitney U-test was used to evaluate markers scored semiquantitatively, and the χ2 test was used to evaluate markers scored as 
present or absent. Results are expressed as median (range), and markers evaluated as present or absent are expressed as percentage of positive 
results. P < 0.05 was considered statistically significant. PsA, psoriatic arthritis.Available online http://arthritis-research.com/content/7/3/R569
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increased presence of CD68+ macrophage-like synoviocytes,
although macrophage-derived pro-inflammatory cytokines
such as tumour necrosis factor-α were also found abundantly
in PsA synovium [8,31-33]. Apart from a difference in CD68+
macrophages and the somewhat unexpected presence of
PMCs in PsA synovitis [8,28], no major differences in infiltrat-
ing cell populations were described between PsA and RA.
Although these differences between PsA and RA are of inter-
est, it should be highlighted that these reports did not clearly
distinguish between different clinical subtypes of PsA and did
not compare PsA with SpA.
Considering that the oligoarticular form of PsA might belong
to the SpA concept, both the present study and previous
reports of our group indicate similar differences between SpA
and RA as those described between PsA and RA: higher lining
layer thickness in RA, but more pronounced vascularity, pres-
ence of polymorphonuclear cells and presence of the
CD163+ macrophage subset in SpA.[14,16,19]. However,
we could not confirm earlier reported differences in the pres-
ence of CD68+ macrophages between the disease groups
[8]. These findings of the present study are in agreement with
our previous reports in SpA [16,19], in which we indicated
that the increased synovial infiltration with CD163+ macro-
phages – a subset that may play an important role in innate
immune inflammation – is not paralleled by an increase in glo-
bal macrophage number, as detected using the pan-macro-
phage marker CD68. This is also in agreement with a recent
independent study [34] comparing PsA with RA, in which no
difference was found in the number of CD68+ macrophages
between the diseases.
In order to confirm whether similarities between SpA and PsA
exist, as suggested by these independent studies, the present
study provides a direct comparison of oligoarticular PsA with
RA and with nonpsoriatic SpA. Our findings clearly demon-
strate the resemblance between oligoarticular PsA and SpA
synovium, whereas oligoarticular PsA synovium is significantly
different from RA in terms of lining layer hyperplasia and PMC
infiltration. Having previously indicated the importance of local
disease activity but not disease duration in the assessment of
synovial histopathology, the present study furthermore pro-
vides evidence that the obtained results are not biased by dif-
ferences in treatment between the groups. Confirming the
observations of other recent studies [19,35,36], these data
certainly do not suggest that DMARD and/or corticosteroid
treatment have no influence on synovial histopathology [23-
27] but they indicate that global synovial histopathology is not
altered in the case of persistent synovitis despite DMARD
and/or systemic corticosteroid treatment.
Bearing in mind that subclassification of PsA is based on the
pattern of peripheral joint involvement [6,7], it is surprising
that, until now, no synovial histology data were available detail-
ing oligoarticular PsA, which is thought to be related to SpA,
and polyarticular PsA, which can mimic RA. Using histological
parameters that discriminate between SpA and RA, such as
lining layer thickness, degree of vascularity, presence of PMCs
and CD163 expression, we were unable to demonstrate any
significant differences between oligoarticular and polyarticular
PsA. In addition, earlier reported markers distinguishing PsA
from RA, such as CD68 and E-selectin, appeared not to be dif-
ferentially expressed between oligoarticular and polyarticular
PsA [8,37]. Considering the discrepancies with regard to
published data on CD68 and E-selectin expression between
PsA and RA, one should consider potential biases in study
populations or in treatment schedules. Moreover, intracellular
citrullinated proteins and Mab-12A staining, which are highly
specific for RA and were found in approximately half of the RA
synovia [17,18], were not detected in the PsA cohorts. These
data provide the first clear evidence that polyarticular PsA
does not exhibit RA-specific synovial features and that the
synovial histopathology of PsA, either oligoarticular or polyar-
ticular, is more closely related to SpA than to RA.
Apart from global histological features, a number of studies
have analyzed more specific molecular systems in PsA syn-
ovium, including S100 proteins. The calcium-binding granulo-
cyte protein S100A12 was recently described in PsA
synovium [10]: although the number of analyzed samples was
too small to allow statistical comparison, a specific expression
in PsA as compared with RA was suggested. In the present
study we confirmed both the presence and the staining pat-
tern of S100A12 in PsA synovium, but neither synovial tissue
Figure 2
Synovial expression of S100A12 in psoriatic arthritis (PsA), nonpsoriatic spondyloarthropathy (SpA; ankylosing spondylitis [AS] + undifferentiated  spondyloarthropathy [USpA]) and rheumatoid arthritis (RA) Synovial expression of S100A12 in psoriatic arthritis (PsA), nonpsoriatic spondyloarthropathy (SpA; ankylosing spondylitis [AS] + undifferentiated 
spondyloarthropathy [USpA]) and rheumatoid arthritis (RA). (a) PsA: lining = 0, sublining = 1 (original magnification 640×); (b) nonpsoriatic SpA: 
lining = 0, sublining = 2 (original magnification 640×); and (c) RA: lining = 0, sublining = 2 (original magnification 640×).Arthritis Research & Therapy    Vol 7 No 3    Kruithof et al.
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analysis nor synovial fluid measurements identified differences
between PsA, SpA and RA. Two other S100 proteins
(S100A8 and S100A9, respectively named myeloid-related
protein [MRP]8 and MRP14), which are found in both infiltrat-
ing PMCs and monocytes, were recently described in different
types of inflammatory arthritis [36-40]. Similar to the findings
of the present study, the expressions of these MRPs in syn-
ovium and synovial fluid were different between SpA and RA
but not between PsA and nonpsoriatic SpA [36]. Furthermore,
we recently provided evidence that the effect of tumour necro-
sis factor-α blockade with infliximab on MRPs, as well as on
global histological features, was similar in PsA and in nonpso-
riatic SpA, further supporting the concept that peripheral joint
disease is closely related in both diseases [41,42].
Nevertheless, the data provided by the present study and the
resulting hypothesis require some critical comments. First, it
should be noted that all patients included in the present study
had an active knee synovitis, which could bias the study pop-
ulation by excluding polyarticular PsA with predominant or
exclusive involvement of hand and feet joints. In addition,
DMARD therapy has been shown to represent a confounding
factor in terms of the pattern and number of swollen joints in
established PsA; patients with polyarticular joint involvement
may therefore be under-represented in our patient cohort [7].
Moreover, because occasional evolution to polyarticular dis-
ease suggests that PsA is a more systemic disease than is
nonpsoriatic SpA, it should be further investigated whether
there are specific histological alterations in clinically unin-
volved joints in PsA versus AS and USpA. Second, more sen-
sitive scoring (digital image analysis versus semiquantitative
scoring) or detection methods might have revealed small dif-
ferences that could have been overlooked in the present study.
However, such small differences should be considered in the
light of their likelihood of being reproduced on the one hand
and their biological relevance on the other [43].
A third criticism of the present study is that it addressed a wide
range of histopathological markers that are known to discrimi-
nate either PsA or SpA from RA, but the resulting concept
requires confirmation by studies of cellular and molecular play-
ers, which are crucially involved in the pathogenesis of periph-
eral synovitis. Therefore, novel mediators identified in vitro or
in animal models of PsA should be further evaluated. Consid-
ering the specific radiological features of peripheral joint
involvement in PsA, an interesting issue – which was not
addressed in the present study – is the synovial mechanism
involved in cartilage and/or bone destruction. However, we
recently investigated a set of metalloproteinases and their
inhibitors in a similar study [35] that indicated that there was
no difference in their synovial expression between SpA and
RA. Surprisingly, the minor differences between PsA and
nonpsoriatic SpA indicated less pronounced expression of
MMP-1 and MMP-2 in PsA.
Another recent study [44] demonstrated that synovial osteo-
clasts and the receptor activator of nuclear factor-κB (RANK)/
RANK ligand system, which are known to play a crucial role in
bone degradation in RA, were also clearly present in PsA syn-
ovium. However, a systematic comparison of synovial osteo-
clasts and RANK/RANK ligand in PsA, SpA and RA remains
to be conducted. Taken together, these three issues indicate
that the absence of histopathological differences between
PsA and non-psoriatic SpA in the present study does not indi-
cate that these conditions are similar. Further studies are
needed to address these issues in greater detail.
Conclusion
The present study is the first to provide detailed comparisons
of PsA synovitis with both RA and SpA, and of oligoarticular
with polyarticular PsA synovitis. It indicates that the synovial
histopathology of PsA, either oligoarticular or polyarticular,
resembles SpA more than it does RA. These biological data
do not support the clinical subclassification of PsA in a polyar-
ticular RA-like and an oligoarticular SpA-like subtypes, and
more importantly, they emphasize the need of more specific
analyses of cellular and molecular characteristics, especially
those that are involved in cartilage and bone pathology, to
unravel the pathogenetic and phenotypic differences and
similarities.
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